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Abstract
Aberrant DNA methylation is one of the most frequent alterations in patients with Acute Lymphoblastic Leukemia (ALL).
Using methylation bead arrays we analyzed the methylation status of 807 genes implicated in cancer in a group of ALL
samples at diagnosis (n=48). We found that 154 genes were methylated in more than 10% of ALL samples. Interestingly,
the expression of 13 genes implicated in the TP53 pathway was downregulated by hypermethylation. Direct or indirect
activation of TP53 pathway with 5-aza-29-deoxycitidine, Curcumin or Nutlin-3 induced an increase in apoptosis of ALL cells.
The results obtained with the initial group of 48 patients was validated retrospectively in a second cohort of 200 newly
diagnosed ALL patients. Methylation of at least 1 of the 13 genes implicated in the TP53 pathway was observed in 78% of
the patients, which significantly correlated with a higher relapse (p=0.001) and mortality (p,0.001) rate being an
independent prognostic factor for disease-free survival (DFS) (p=0.006) and overall survival (OS) (p=0.005) in the
multivariate analysis. All these findings indicate that TP53 pathway is altered by epigenetic mechanisms in the majority of
ALL patients and correlates with prognosis. Treatments with compounds that may reverse the epigenetic abnormalities or
activate directly the p53 pathway represent a new therapeutic alternative for patients with ALL.
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Introduction
Acute lymphoblastic leukemia (ALL), the most common kind of
cancer in children, is associated with a number of genetic lesions
responsible for impairment of normal cellular behavior. Chromo-
somal translocations identify unique subtypes of the disease [1],
and although detected in less than 50% of patients with B-ALL
and in a significantly lower percentage of T-ALL, they have been
associated with specific prognostic groups [2]. These translocations
usually activate transcription factors responsible for the control of
cell differentiation, proliferation and apoptosis [3]. Recent
evidence suggests that translocations act in concert with other
genetic lesions to induce overt leukemia including deletion of genes
such as cyclin-dependent kinase inhibitor 2A gene (CDKN2A) [4]
or the more recently described deletion of IKZF1 (Ikaros) [5].
Unlike solid tumors, point mutations involving oncogenes or
tumor suppressor genes are rarely seen in patients with ALL [6].
TP53 is one of the genes most frequently mutated in cancer, with
inactivating mutations present in over 50% of patients with solid
tumors. However, less than 3% of patients with ALL show
mutations of TP53, despite the fact that ALL cells present an
abnormal resistance to apoptosis, a hallmark of deregulated p53
pathway [7]. The low percentage of TP53 mutations in ALL
patients as well as the resistance to apoptosis suggest that
regulation of apoptosis in ALL could be mediated by other
mechanisms involved in the abnormal function of the p53 pathway
or p53 independent mechanisms, including the deregulation of
genes of the BCL2 family such as BCL2, BAX, BCL-XL,
mechanisms that should be explored in order to improve our
understanding of the pathogenesis of the disease
The role of aberrant epigenetic modifications in cancer
development and particularly in hematological malignancies such
as acute leukemias and myelodysplastic syndromes has clearly
been recognized in the last years [8,9]. Several groups have
demonstrated that the abnormal methylation of multiple genes is
common in patients with ALL and it is associated with the
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pathogenesis and prognosis of the disease [10,11,12,13,14]. This
alteration represents an alternative mechanism to gene suppressor
mutations and deletions and may affect indirectly the function of
these genes in a similar fashion as mutations of TP53 [7].
In the current study by analyzing 48 ALL patients samples using
methylation bead arrays and subsequent validation of the results in
a second series of 200 patients we demonstrate that aberrant DNA
methylation is a common epigenetic alteration in ALL. Some of
the genes found inappropriately methylated are involved in the
p53 pathway suggesting that despite the lack of activating
mutations of TP53 in ALL, there is an abnormal function of
p53 mediated by epigenetic mechanisms. Hypermethylation of
genes implicated in the TP53 pathway is a poor independent
prognostic factor in patients with ALL and the use of compounds
that can directly or indirectly activate this pathway opens new
therapeutic strategies for patients with ALL.
Results
ALL displays marked aberrant promoter DNA
methylation
In the initial methylation profiling analysis using GoldenGateH
Methylation Cancer Panel I array we included 17 samples from
healthy donors (7 PBMNC, 5 CD19-positive cells from PBMNC
and 5 CD3-positive cells from PBMNC), 48 ALL patient samples
(17 BCR-ABL1
+, 7 TEL-AML1
+, 3 MLL
+, 3 MYC
+, 2 E2A-
PBX1
+, 4 common ALL, 1 pro-B ALL, 1 pre-B ALL and 10 T-cell
ALL) and 4 ALL cell lines. Additionally, 5 of the 48 ALL samples
showed more than 5% CpGs with detection p values .0.01
(Figure S1) and therefore were removed from further analyses.
ALL samples (43 patients and 4 cell lines) had higher levels of de
novo DNA methylation than control samples (n=17) and
clustered separately from them (Figure S2). The analysis of
differentially methylated genes (DMA) is shown in Table S5. A
total of 460 CpGs (299 genes) were hypermethylated in at least one
ALL sample and 216 CpGs (154 genes) were hypermethylated in
more than 10% of ALL samples (Figure 1A). Eighty eight CpGs
(75 genes) were hypomethylated in at least one ALL and 24 CpGs
from 22 genes were hypomethylated in more than 10% of ALLs
(Figure 1B).
Previous reports have shown that genes acquiring the novo
hypermethylation in cancer are targeted by the polycomb
repressor complex 2 (PRC2) in embryonic stem cells (ESCs),
indicating that such polycomb target genes seem to be predisposed
for cancer-specific hypermethylation. This phenomenon has been
shown for several tumors such as breast or colon cancer [15,16]. In
order to determine whether this also occurs in ALL, we analyzed
the level of enrichment for PRC2 targets in ESC [17] in different
ALL methylation groups. Interestingly, 47.2% of the genes
aberrantly methylated in more than 10% of the ALL samples
were PRC2 targets in ESC (only 21% of the genes included in the
array were PRC2 targets; p,0.001). In contrast, only 9.1% of the
hypomethylated genes were PRC2 targets in ESC. These findings
suggest that indeed ALL-specific hypermethylation affects prefer-
entially genes marked for repression by PRC2 in ESCs.
As hypermethylation frequently targets genes with dense CpG
islands, we also studied the CpG content of differentially
methylated groups in ALL samples. Among the 759 cancer
related genes included in the array 58.8% corresponded to high
CpG promoters (HCP), 14% to intermediate CpG (ICP) and
27.2% to low CpG (LCP) [18]. Hypomethylated genes were
enriched in LCP (59.1%) (p=0.03 in comparison with the whole
group) while an enrichment of HCP promoters (78.2%) was
observed among hypermethylated genes (p,0.001). These results
indicate that ALL hypermethylation occurs in dense CpG islands
while hypomethylation is more frequently observed in genes with
low-density CpG dinucleotides.
The results from the microarrays were confirmed by the analysis
of 12 genes included in the array by standard MSP and 3 out of 12
genesbypyrosequencing(Figure S3andS4).Themethylationstatus
of these genes was analyzed in two ALL derived cell lines (TOM-1
andNALM-20), humanmalegenomic DNAuniversallymethylated
for all genes and peripheral blood sample of healthy donor and
compare with the equivalent samples in the array. By MSP, 8 out of
12 genes (CDH1, CDH13, DBC1, SFRP1, SYK, TAL1, TP73 and
WNT5A) were methylated in both ALL derived cell lines, 3 were
unmethylated (CDKN1A, FHIT and RASSF1A) and 1 was methyl-
ated in TOM-1 cell line and unmethylated in NALM-20 cell line
(MGMT) (FigureS2 and S3)[10,19,20,21,22].Bypyrosequencing,2
out 3 genes (SYK and TAL1) were methylated in both ALL derived
cell lines and 1 was methylated in TOM-1 cell line and
unmethylated in NALM-20 cell line (MGMT) (Figure S3). The
results obtained from the array and the individual analyses by MSP
or pyrosequencing were highly concordant (Median of Beta values
for genes unmethylated by MSP was 0.04 whereas for genes
methylated by MSP was 0.84). These results indicate, as previously
shown [23] that individual CpGs from methylation arrays can be
taken as surrogate markers for the methylation status of the
respective promoter regions in ALL.
TP53 pathway deregulation in ALL is associated with
abnormal DNA hypermethylation of gene promoters
implicated in p53 function
Someofthegenesidentifiedashypermethylatedbythearrayshave
already been described to be epigenetically regulated in ALL
[10,19,20,21,22]. Four of these hypermethylated genes (DBC1,
TP73, DAPK1 and CDKN1C)h a v eb e e ni m p l i c a t e di nt h eTP53
pathway in ALL. Due to the fact that deregulation of the TP53
pathway is a hallmark of cancer while function of p53 is abnormal in
A L Ld e s p i t et h er a r eo c c u r r e n c eo fTP53 mutations in ALL [7], the
abnormal hypermethylation of these genes prompted us to perform a
new unsupervised analysis with all the genes implicated in the TP53
pathway included in the Illumina array. The hierarchical clustering
including all samples demonstrated that TP53 pathway genes are
aberrantly methylated in ALL samples and that this alteration
accurately differentiates ALL from control samples (Figure 2).
To further analyze the hypothesis that the TP53 pathway might
be inactivated or blocked in ALL independently of TP53
mutations, we extended the analysis of DNA methylation by
MSP to a total of 24 genes implicated in the TP53 pathway using
six derived ALL cell lines (Figure 3). These genes are implicated in
p53 regulation and p53 dependent cell cycle and apoptosis while
all of them have a typical CpG island. Interestingly 13 of the 24
genes were aberrantly hypermethylated in ALL derived cell lines
(Figure 4A), of which 84.6% (11/13) were HCP, 7.7% (1/13) ICP
and 7.7% (1/13) LCP. Unlike the whole group of genes
differentially methylated in ALL, only 3 of the 13 genes
(23.07%) of the TP53 pathway were PRC2 targets in ESC
(Figure 4B). Nine of the 13 methylated genes were involved in the
regulation of p53 dependent apoptosis (DBC1, hsa-miR-34b, hsa-
miR-34c, POU4F2, AMID, APAF1, ASPP1, TP73 and NOXA), 2 of
them in p53 dependent cell cycle regulation (POU4F1 and
CDKN1C) and the other two in p53 regulation (LATS2 and
DAPK1) (Figure 4B). While we have previously demonstrated most
of these genes to be regulated by hypermethylation in ALL
[11,19], that was not the case for AMID, POU4F1, POU4F2 and
hsa-miR-34b/c. Expression of these five genes was decreased in
TP53 Pathway Methylation in ALL
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5-aza-2-deoxycytidine (added one time only) during 4 days,
induced a demethylation and upregulation of gene expression
(Figure S5). These results indicate that DNA methylation of p53
dependent genes is an important mechanism associated with
abnormal function of the TP53 pathway in ALL.
Activation of TP53 pathway induces cell apoptosis in ALL
In order to prove that abnormal hypermethylation of genes
implicated in the TP53 pathway could be responsible at least in
part for the resistance to apoptosis in ALL, TOM-1 and NALM-
20 cells were treated with either a demethylating agent (5-aza-29-
deoxycytidine), a caspase-8 activator (Curcumin) that induces
Figure 1. Hierarchical cluster analysis based on abnormally methylated genes in more than 10% of ALL samples. A. Hypermethylated
genes in more that 10% of ALL samples. B. Hypomethylated genes in more than 10% of ALL samples. The top bar beneath the dendrogram refers to
the subtypes of ALL and specific controls from healthy donors, while the lower bar indicates ALL or control. Subtypes of leukemia or controls are
color coded (ALL: Acute Lymphoblastic Leukemia; PBMNC: Peripheral Blood mononuclear cells from healthy donors, CD19
+ cells from PB and CD3
+
cells from PB). Red: methylated; Green: non-methylated.
doi:10.1371/journal.pone.0017012.g001
TP53 Pathway Methylation in ALL
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inhibitor of MDM2 and thus an activator of the p53 pathway. We
have previously demonstrated that TOM-1 shows no TP53
mutation or deletion while NALM-20 shows a deletion of one
TP53 allele [11]. Treatment of ALL cells with 5-aza-29-
deoxycytidine induced a non-specific demethylation and upregu-
lation of expression of genes implicated in TP53 pathway (Figure
S4), as well as an increase in apoptosis of TOM-1 and NALM-20
cells as measured by Annexin-V, caspase-3 or PARP expression
(Figure 5A).
Figure 2. Hierarchical cluster analysis of TP53 pathway genes included in the beadarray. The top bar beneath the dendrogram refers to
the subtypes of ALL and specific controls from healthy donors, while the lower bar indicates ALL or control. Different subtypes of leukemia or controls
are color coded (ALL: Acute Lymphoblastic Leukemia; PBMNC: Peripheral Blood mononuclear cells from healthy donors, CD19
+ cells from PB and
CD3
+ cells from PB). Red: methylated; Green: non-methylated.
doi:10.1371/journal.pone.0017012.g002
Figure 3. Outline of the genes involved in the TP53 pathway.
doi:10.1371/journal.pone.0017012.g003
TP53 Pathway Methylation in ALL
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Curcumin, pro caspase 8 was activated leading to an increase in
apoptosis in both TOM-1 and NALM-20 cells (Figure 5B, C).
Interestingly, beside an increase in apoptosis, treatment with
Curcumin induced an increase in acethylation of histone 3 and
demethylation of TP53 pathway genes (Figure 5C, D) suggesting a
role as an epigenetic drug for this compound. Finally, to examine if
constant activation of TP53 could induce a beneficial effect, ALL
cells were treated with the MDM2 inhibitor Nutlin-3. Nutlin-3
induced apoptosis of TOM-1 cells which was associated with p53
accumulation, upregulation of CDKN1A transcription and an
increase in p21 protein as a reflection of p53 dependent induction
of apoptosis. In contrast, treatment of NALM-20 cells with Nutlin-
3 did not induced p53 accumulation or increase of apoptosis,
probably related to the fact that one allele of TP53 is deleted in
NALM-20 (Figure 5E).
Hypermethylation of TP53 pathway genes predicts
clinical outcome in ALL patients
We next analyzed the methylation status of the 13 genes
inappropriately methylated in ALL cell lines in a group of 200
samples from ALL patients at diagnosis. The methylation
frequencies (in descending order) for each of the 13 genes were:
41% for POU4F2, 36% for hsa-miR-34bc, 28% for NOXA, 24% for
LATS2, 24% for ASSP1, 20% for APAF1, 19% for AMID, 17% for
TP73, 16% for DBC1, 12% for DAPK1, 11% for POU4F1 and 6%
for CDKN1C. No methylated genes were found in 43 of 200
patients (non-methylated group, 22%) whereas most ALLs [157
(78%) of 200] had at least one gene methylated (methylated
group). Based in the presence of gene promoter methylation of the
13 genes, the analysis performed using GENESIS (version 1.7.5)
clustered separately patients with non-methylated genes and
patients with at least one gene methylated (Figure 6). Among
patients in the methylated group, 61% presented two or more
genes methylated while none of the patients were found to have
methylation of more than 9 genes. These results indicate that
DNA methylation of TP53 pathway genes is frequent in ALL and
usually involves several genes. Similar to ALL cell lines, genes
involved in p53 dependent apoptosis were more frequently
methylated (70% of the patients) than p53 cell cycle dependent
genes (15%) or p53 regulatory genes (32%). Methylation was more
frequently observed in adult ALL than in children ALL (85% vs
70%, P=0.015). Furthermore, the analysis clustered patients in
only 2 groups, one including patients with none of the 13 genes
methylated and another one including 1 or more methylated
genes, reinforcing the hypothesis that the presence of a single
methylated gene, more than the number of methylated genes is
what confers a poor prognosis in ALL.
Figure 4. TP53 pathway genes are methylated in ALL cell lines. A. MSP analysis of the methylated and un-methylated sequences of genes
implicated in TP53 pathway in ALL derived cell lines. UC: un-methylated control (DNA of peripheral blood from a healthy donor). MC: universally
methylated control, M: 100 bp molecular marker. B. Graphic representation of the results of methylation of genes of TP53 pathway and its
involvement in TP53 dependent apoptosis, cell cycle or regulation of TP53. Information regarding CpG composition and whether these genes are
target of PCR2 in ESC is shown. Red: methylated, Green: unmethylated.
doi:10.1371/journal.pone.0017012.g004
TP53 Pathway Methylation in ALL
PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e17012Figure 5. Activation of TP53 function induces cell apoptosis in ALL. TOM-1 and NALM-20 cells were treated with 5-aza-2-deoxycitidine,
Curcumin and Nutlin-3. A. Apoptosis induced by 5-aza-2-deoxycitidine treatment: Annexin V analysis by flow citometry (grey: early apoptotic; black:
late apoptotic/death cells), Caspase-3 analysis by flow citometry and Western blot analysis of the 85-kDa fragment of PARP. B–D. Curcumin
treatment; Western blot analysis and quantification of Caspase 8. PRO-C8: full length caspase-8 fragment; p43/p41: cleaved intermediate p43/p41
fragment of caspase-8 and p18: caspase-8 active fragment p18. Numbers at the bottom of the figure represent the quantification of these three
fragments of caspase-8 (B); Activation of apoptosis measure by Annexin V (grey: early apoptotic; black: late apoptotic/death cells) and Caspase-3
(FACS) and by the detection of the 85-kDa fragment of PARP (C). Upregulation in the amount of acetylated histone 3 by Western blot is shown. Total
histone 3 and b-actin are loading controls (C); qRT-MSP and pyrosequencing of hypermethylated genes implicated in TP53 pathway before and after
treatment with Curcumin (D). E. Western blot analysis of p21 and p53, levels of CDKN1A and TP53 mRNA by Q-RT-PCR and detection of apoptosis by
Annexin V (grey: early apoptotic; black: late apoptotic/death cells), Caspase-3 and detection of the 85-kDa fragment of PARP by western blot after
treatment with Nutlin-3. b-actin was used as a loading control in all cases. A,C and E, the mean 6 SD of at least 3 different experiments is shown. A-
E, a representative example of at least 3 different experiments is shown.
doi:10.1371/journal.pone.0017012.g005
TP53 Pathway Methylation in ALL
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groups were 91% (39/43) and 84% (133/157), respectively
(P=0.3) with an overall CR rate of 86%. Patients in the non-
methylated group had a lower relapse rate than patients in the
methylated group (9/43, 21% vs 73/157, 46%, P=0.001).
Mortality rate was also lower for the non-methylated group
compared with the methylated group (8/43, 19% versus 88/157,
56%, P,0.001). Similar results were observed when adults and
children were analyzed separately: relapse rate was 18% for
children in the non-methylated group versus 37% for the
methylated group, P=0.08; mortality rate was 4% for children
in the non-methylated group versus 27% for methylated group,
P=0.01); relapse rate and mortality in adults were 31% for non-
methylated group versus 65% for methylated group, P=0.03 and
44% for non-methylated group versus 76% for methylated group,
P=0.01 respectively.
Survival data were available on the whole cohort, with a median
follow-up until censoring from any cause of 50.9 months (95% CI:
35.9–66 months). Median follow-up times to relapse and death
were 24 months (95% CI: 12.7–35.3 months) and 13.2 months
(95% CI: 10.9–15.4 months), respectively. Disease free survival at
16 years was 76% and 43% for non-methylated and methylated
group (P=0.0006) (Figure 7A). Among children, the 14-year DFS
was 81% for non-methylated group and 61% for methylated
group (P=0.05) (Figure 7B) while adult ALL patients had a 15-
year DFS of 66% for non-methylated group and 27% for
methylated group (P=0.02) (Figure 7C). The actuarial overall
survival (OS) at 16 years calculated for all leukemic patients was
81% for non-methylated patients and 41% for methylated patients
(P=0.0001) (Figure 7D). Significant differences were observed in
the actuarial OS among non-methylated and methylated groups in
the separate analyses of children (96% vs 72%, P=0.01)
(Figure 7E) and adults (55% vs 20%, P=0.03) (Figure 7F). Event
free survival at 15 years was 69% and 32% for non-methylated
and methylated group (P=0.0004) (Figure 7G). Among children,
the 14-year EFS was 81% for non-methylated group and 58% for
methylated group (P=0.04) (Figure 7H) while adult ALL patients
had a 15-year EFS of 49% for non-methylated group and 16% for
methylated group (P=0.05) (Figure 7I). The multivariate analysis
of potential prognostic factors demonstrated that hypermethyla-
tion was an independent prognostic factor for DFS (P=0.006)
(Table S6), OS (P=0.005) (Table S7) and EFS (P=0.01)
(Table S8).
Discussion
The number of genes regulated by epigenetic mechanisms
including DNA hypermethylation and histone modifications in
patients with ALL has raised significantly in the last few years,
indicating that epigenetic changes play a significant role in the
pathogenesis and prognosis of the disease [10,12,14,24,
25,26,27,28]. Our current results not only further increase the
number of genes described as aberrantly methylated in ALL but
more importantly indicate that one of the pathways most
frequently deregulated in different cancers such as TP53 is altered
in ALL not due to genetic events but rather to the abnormal
hypermethylation of many genes involved in p53 induced
apopotosis, cell cycle and p53 regulation. The higher frequency
of hypermethylation among gene promoters with HCP and a
higher percentage of hypomethylated genes among LCP promot-
ers supports the model recently described in which de novo
methylation in cancer mainly affects genes with dense CpG islands
[23].
Recent studies have described genome wide methylation in
ALL using different approaches such as differential methylation
hybridization [24], CGP-island arrays [25,26,27], MCA/human
proximal promoter DNA microarray [14] or HELP assays [28].
These methods vary in terms of number and type of genomic
regions detected, quantification accuracy and resolution. The
CpG-specific array used in the present study is highly
quantitative and shows a single-base resolution. However, as
compared to other arrays with higher coverage, it can only
detect changes in 800 cancer-related genes and 1 to 3 CpGs are
studied per gene. Even considering this lower coverage, we could
detect a large number of genes (n=154) hypermethylated in
more than 10% of the ALL samples. Among the studies quoted
above, those including more than 400 ALL patients have shown
that certain genetic subtypes maybe distinguished based on their
Figure 6. Hierarchical cluster analysis based on the methylation status of 13 genes of TP53 pathway in ALL samples. Different
subtypes of leukemia are coded by a specific colour. Yellow: ALL samples without methylation, Blue: ALL samples with a least one methylated gene.
doi:10.1371/journal.pone.0017012.g006
TP53 Pathway Methylation in ALL
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subgroups of ALL such as MLL leukemia, demonstrating that
hypermethylation is associated with a worse prognosis [24]. In
our study there was no specific methylation profiles associated
with the cytogenetic group probably due to the limited number
of patients per group.
Figure 7. Survival curves of Kaplan-Meier. DFS curves for all patients enrolled in this study (panel A), childhood ALL (B) and adult ALL (C)
according to the methylation profile. OS curves for all patients enrolled in this study (D), childhood ALL (E) and adult ALL (F) according to the
methylation profile. EFS curves for all patients enrolled in this study (G), childhood ALL (H) and adult ALL (I) according to the methylation profile.
doi:10.1371/journal.pone.0017012.g007
TP53 Pathway Methylation in ALL
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ment of the disease; however, as these may arise in utero, there is
long latency before overt ALL, showing that additional changes
are needed [29]. The potential to contribute to leukemia
development varies among different translocations so while
BCR-ABL1 is strong leukemogenesis inducer, other translocations
such as TEL-AML1 requires more events. Gene deregulation
through hypermethylation may contribute to the transformation of
the hematopoietic cells. In line with this hypothesis, BCR-ABL1+
ALL samples contained a smaller number of hypermethylated
genes than TEL-AML1 ALL or T-ALL samples which could be
related to the higher leukemogenesis potential of this oncogene.
The results are also consistent with previous observations from our
group in patients with Ph
+ CML in which DNA hypermethylation
is an infrequent event [23,30] with DNA hypomethylation being a
more representative epigenetic alteration [31].
Recent studies have demonstrated that genes inappropriately
hypermethylated in cancer are frequent targets of PRC2 in
embryonic stem cells supporting the hypothesis that de novo
methylation is pre-programmed by an established epigenetic
system that predisposes tumor suppressor genes to DNA
hypermethylation [15,16]. This hypothesis is also supported by
our results showing that almost half of the genes aberrantly
methylated in more than 10% of the ALL samples were PRC2
targets in embryonic stem cells [17]. Whether the epigenetic
alteration could be the initiating event that predisposes a precursor
cell to transformation or alternatively the genetic changes (such as
translocations) are the initial transformation event that predisposes
the cells to further epigenetic changes is unclear. Experimental
data supports that certain genetic alterations such as the PML-
RAR fusion protein has the potential to form a stable complex
with DNMT1 and DNMT3a that subsequently can induce gene
promoter hypermethylation [32].
Frequent and simultaneous aberrant methylation of genes
implicated in TP53 pathway indicates that, although indirectly
and against previous knowledge, TP53 is altered in a high
percentage of ALL patients, as it is the case in other types of
cancer. Hypermethylation of these 13 genes have been described
in independent studies in other types of tumors such as DBC1 in
lymphomas and lung cancer [33], LATS2 in head and neck
squamous cell carcinoma, astrocytoma or breast cancers [34],
ASPP1 in hepatocellular carcinoma [35], DAPK1 in Multiple
Myeloma [36] and chronic lymphocytic leukemia [37], APAF1 in
acute myeloblastic leukaemia [38] and gastric cancer [39], TP73
in cervical carcinomas [40], CDKN1C in diffuse large B cell
lymphoma [41] and pancreatic ductal neoplasms [42] and finally,
hsa-miR-34b/c in ovarian and colorectal cancers [43]. The use of
the bead-array based technology in patients with lymphoma [23],
colorectal cancer [44] and glioblastoma multiforme [45] have
shown that similar to what we observed in ALL, a frequent and
simultaneous methylation of some of these genes is a frequent
event in other tumors indicating that in addition to classical
mutations and deletions of TP53, we should take into account
indirect inactivation of TP53 in other types of human cancers.
An important clinical implication from our results is that we
establish TP53 pathway as an attractive therapeutic target in ALL.
The development of drugs that target the most frequent alterations
in human cancer such as the universal alteration of the TP53
pathway has been a major quest in cancer research [46].
Currently, two different approaches are being used: a molecule
that directly activate p53 by blocking protein-protein interactions
and compounds that trigger indirectly the stimulation of TP53
system [46] such as Nutlin-3, a small molecule antagonist of
MDM-2 that disrupts the MDM2-p53 interaction resulting in p53
stabilization and activation of p53 function [47]. Treatment of
ALL cells with Nutlin-3 induced cell apoptosis in TOM-1 which
was consistent with stabilization of the p53 protein (Figure 5) but
not in NALM-20 cells, probably because these cells have the
deleted one allele of TP53.
Curcumin is the natural polyphenolic antioxidant and most
active component of curry spice. It has been used for over 4000
years in the traditional Indian, Chinese or Arabic medicine and
has demonstrated a low toxicity in humans even at high doses
showing a remarkable anti-inflammatory, antioxidant, pro-apo-
ptotic and anti-tumor properties [48]. We used Curcumin in our
study based on its potential to directly induce apoptosis by
activation of caspases thus preventing the need for functional p53.
Interestingly, Curcumin in addition to activation of caspase 8, was
able to induce epigenetic mechanisms such as acetylation of
histone 3 or DNA demethylation suggesting a role for these
mechanisms in apoptosis induced by Curcumin in ALL cells,
making this compound an attractive candidate for further studies.
In summary, we show that aberrant DNA methylation is
common and occurs simultaneously in several genes in ALL cells,
directly affecting an essential pathway implicated in tumorigenesis
such as the tumor suppressor gene TP53. Hypermethylation of
genes implicated in TP53 pathway is an independent prognostic
factor for DFS, OS and EFS in patients with ALL. The use of
compounds that can directly or indirectly activate this pathway
such as 5-aza-2-deoxycitidine, Curcumin or Nutlin-3 opens new
therapeutic strategies for patients with ALL.
Materials and Methods
Human samples and cell lines
The following ALL-derived cell lines (TOM-1, NALM-20, MY,
LOUCY, TANOUE and MOLT-4) were used for in vitro studies.
Cell lines were maintained in culture in RPMI 1640 medium
supplemented with 10% fetal bovine serum with 1% penicillin-
streptomicin and 2% hepes at 37uC in a humid atmosphere
containing 5% CO2. Bone marrow mononuclear cells were
obtained at diagnosis from patients with ALL after informed
consent was obtained from the patient or the patient’s guardians,
in accordance with the Declaration of Helsinki. This study was
approved by the Research Ethics Committee at the University of
Navarra. Some of the samples were obtained more than 15 years
ago. In these cases, consent was verbal and as such was accepted
by the Research Ethics Committee. Samples from recent patients
were obtained with written informed consent. Samples were
divided in 2 groups for methylation arrays (48 patients) and validation
analysis (200 patients). Diagnosis was established according to
standard morphologic, cytochemical and immunophenotypic
criteria and all patients were enrolled in successive multicenter
studies of the ‘‘Programa para el estudio y tratamiento de las hemopatias
malignas’’ (PETHEMA) Spanish study group. Samples used in the
arrays included BCR-ABL1
+ ALL t(9;22) (n=17), TEL-AML1
+
t(12;21) (n=7), MLL
+ (n=3), MYC
+ (n=3), E2A-PBX1
+ t(1;19)
(n=2), common ALL (n=4), pro-B ALL (n=1), pre-B ALL
(n=1) and T-cell ALL (n=10). In the validation group, 200
samples (113 male and 87 female) from patients diagnosed with de
novo ALL between January 1990 and May 2007 were included.
Median age at diagnosis was 17 years (range 0.5–82 years) with 91
children (median age 5, range 0.5–14 years) and 109 adult patients
(median age 36; range 15–82 years). Patients were risk-stratified
according to the therapeutic protocol used, which was always
based on recognized prognostic features (including cytogenetics)
and were entered in ALL protocols of the PETHEMA Spanish
study group. For statistical analyses, children were also grouped
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criteria [49]. The specific PETHEMA ALL treatment protocols in
which these patients entered included ALL-89 (between 1990–
1993; n=48) and ALL-93 (between 1993–2007; n=152). The
design and clinical results of these studies have been previously
reported [50,51,52]. Eighty-two patients relapsed. Forty-two
patients received stem cell transplantation (SCT, 8 autologous,
34 allogeneic) in the first (n=14) or second complete remission
(CR) (n=20). There are 104 patients currently alive. Clinical
characteristics of the patients are listed in Table S1.
For methylation arrays, samples from 17 healthy donors
obtained from male and female Caucasian European volunteers
between 25–40 years old, were included. (Peripheral Blood
Mononuclear Cells n=7; CD19-positive cells from PBMNC
n=5 and CD3-positive cells from PBMNC n=5). CD3
+ and
CD19
+ cells were enriched by Magnetic Cell Sorting using CD3 or
CD19 human microbeads, respectively (Miltenyi Biotec, Cologne,
Germany) and the AutoMACS selection device. In all cases cell
purity was over 90%.
DNA methylation-specific array and data analysis
For genome-wide DNA methylation analyses, we used the
GoldenGateH Methylation Cancer Panel I (Illumina, Inc.), which
contains 1505 CpG sites selected from 807 cancer-related genes.
The experimental protocol, scanning, image processing and data
extraction was carried out as previously described according to the
instructions of the manufacturer [23,53,54]. Before analyzing the
methylation data (so called beta values, which range from 0 for
unmethylated and 1 for completely methylated), we excluded
possible sources of biological and technical biases that could alter
the results. As one copy of chromosome X is methylated in
women, we excluded all 84 CpGs on chromosome X to avoid a
gender-specific bias. Additionally, we evaluated the detection
probabilities (comparing signal intensities against background
noise) for all CpGs and excluded those CpGs with values of
P.0.01 in more than 15% of cases (Figure S1A). From a total of
1505 CpGs included in the array, 60 CpGs showed bad detection
p values (i.e. above 0.01) in more than 15% of cases and
consequently were eliminated from the study. Additionally,
samples with P.0.01 in more than 5% of the CpGs were
removed from the analyses (Figure S1B). Using these criteria, 1367
autosomal CpGs from 759 genes entered further statistical
analyses, and 5 ALL samples were removed because of their poor
quality.
Unsupervised hierarchical clustering was performed using the
Cluster Analysis tool of the BeadStudio software (version 3.2). As
DNA methylation usually follows a bimodal distribution (a gene is
either methylated or unmethylated), a differential methylation
analysis was performed by categorizing the methylation data in
controls and cases. Considering that some genes might be clearly
differentially methylated in a small subset of ALL cases, a CpG
was classified as hypermethylated in ALL when the mean in the
controls was homogeneously below 0.25 (and none of them was
above 0.5) and individual beta values were greater than 0.75 in at
least 10% of the ALL samples. Conversely, a CpG was considered
hypomethylated in ALL when the mean in the controls was
homogeneously above 0.75 (and none of them was below 0.5) and
individual beta values were smaller than 0.25 in at least 10% of the
ALL samples. CpGs that could not be assigned to any of these
groups, v.g. CpGs methylated or unmethylated in cases and
controls, as well as CpGs with mean methylation values between
0.25 and 0.75 (partially methylated) in the control samples, were
not considered for further analyses.
Methylation-Specific PCR (MSP)
DNA of cell lines was extracted using QIAmp DNA Mini Kit
(Qiagen, Hilden, Germany). MSP was used to analyze the
methylation status of the gene promoter region as previously
described [10,55]. This technique is based on a bisulfite treatment
of the DNA that modifies unmethylated but not methylated
cytosines into uracils. 1 mg of genomic DNA was treated and
modified using the CpGenomic DNA modification Kit (Millipore,
Billerica, MA01821, USA). After bisulfite treatment of DNA, ‘‘hot
start’’ PCR was performed for 35 cycles consisting of denaturation
at 95uC for 1 min, annealing at T
a for 1 min, and extension at
72uC for 1 min, followed by a final 72uC for 10 min extension for
all primer sets. Primer sequences of each gene for the
unmethylated and methylated reactions are described in Table
S2 and S3. The products were separated by electrophoresis on
1.8% agarose gel. Bone marrow and peripheral lymphocyte DNA
from healthy donors were used as negative control for methyla-
tion-specific assays. Human male genomic DNA universally
methylated for all genes (Intergen Company, Purchase, NY) was
used as a positive control for methylated alleles. Water blanks were
included with each assay. The results were always confirmed by
repeat MSP assays after an independently performed bisulfite
treatment. Methylation status of AMID, POU4F1, POU4F2, hsa-
miR-34b and hsa-miR-34c CpG islands after 5-aza-2’-deoxycytidine
and DBC1, hsa-miR-34b, hsa-miR-34c, POU4F2, AMID, APAF1,
ASPP1, TP73, NOXA, POU4F1 and LATS2 after Curcumin
treatment was performed by semiquantitative real time methyla-
tion-specific PCR (qRT-MSP) as previously reported [55].
To validate the DNA methylation data generated by BeadArray
technology, methylation-specific-PCR (MSP) of 12 genes were
performed as previously described [10,19,20,21,22,56,57,58]. For
TAL1-MSP, TAL1-MD (5’- GTATAGTTCGGTGGTGGG-
TATTC-3’) and TAL1-MR (5’- CGCACCTAATCCTACTA-
AACGAC -3’) primers were used for the methylated reaction and
TAL1-UD (5’-TTGTATAGTTTGGTGGTGGGTATTT-3’)
and TAL1-UR (5’- CCCACACCTAATCCTACTAAACAAC -
3’) primers for the unmethylated reaction. PCR conditions for
TAL1-MD/TAL1-MR and TAL1-UD/TAL1-UR primers were
94uC for 10 min, followed by 35 cycles at 94uC for 1 min, 60uC
for 1 min and 72uC for 1 min. The final extension was at 72uC for
10 min in both cases. MSP products were separated on a 2%
agarose gel, stained with ethidium bromide and visualized under
UV light. Results were confirmed by repeating bisulfite treatment
and MSP assays for all samples.
DNA methylation analysis by Pyrosequencing
The PCR reactions for pyrosequencing were done with a
biotynilated specific reverse primer and performed as follows.
After bisulfite treatment of DNA, ‘‘hot start’’ PCR was performed
with a denaturalization at 95uC for 10 minutes and for 35 cycles
consisting of denaturation at 95uC for 1 min, annealing at the
specific temperature for each gene for 1 min, and extension at
72uC for 1 min, followed by a final 10 min extension for all primer
sets. Primer sequences of each gene are described in Table S4. The
resulting biotinylated PCR products were immobilized to
streptaviding Sepharose High Performance beads (GE healthcare,
Uppsala, Sweden) and processed to yield high quality ssDNA using
the PyroMark Vacuum Prep Workstation (Biotage, Uppsala,
Sweden), according to the manufacturers instructions. The
pyrosequnecing reactions were performed using the Pyromark
TM
ID (Biotage, Uppsala, Sweden) and sequence analysis was
performed using the PyroQ-CpG analysis software (Biotage,
Uppsala, Sweden). Bone marrow and peripheral lymphocyte
DNA from healthy donors were used as negative control for
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sally methylated for all genes (Intergen Company, Purchase, NY)
was used as a positive control for methylated alleles. Water blanks
were included with each assay. The results were always confirmed
by repeat pyrosequencing assays after an independently performed
bisulfite treatment.
Expression analyses by Q-RT-PCR
Total RNA was extracted from human bone marrow
mononuclear cells or cell lines with Ultraspect (Biotecx, Houston,
TX, USA) following the manufacturer’s instructions. Reverse
transcription and Q-RT-PCR were performed using specific
primers for AMID, POU4F1 and POU4F2 (Table S9). Amplifica-
tion of glyceraldehide-3-phosphate dehydrogenase (GAPD) tran-
script was performed to assess RNA integrity and as a reference
gene using specific primers and TaqMan probe (Hs99999905_m1;
Applied Biosystems, Foster City, CA).
Reverse transcription was performed on 1 mg of total RNA,
after heating at 70uC for 5 min, with random hexamers as
reaction primers. The reaction was carried out at 42uC for 45 min
in the presence of 12 U Avian Myeloblastosis virus reverse
transcriptase (Boehringer-Mannhein, Germany). Q-RT-PCR was
performed in a rapid fluorescent thermal cycler with three-color
fluorescence monitoring capability (LightCycler, Roche Molecular
Biochemicals, Mannheim, Germany), using 1 ml of cDNA in 20 ml
reaction volume with 0.4 mmol/l of each primer, and 2 mlo f1 0
LightCycler FastStar DNA Master SYBR Green I (Roche
Molecular Biochemicals, Mannheim, Germany). The final Mg
2+
concentration in the reaction mixture was adjusted to 3.5 mmol/l.
The following program conditions were applied for Q-RT-PCR
running: denaturation program, consisting in one cycle at 95uC for
8 min; amplification program, consisting in 45 cycles at 95uC for
5s ,6 0 uC for 10 s and 72uC for 15 s; melting program, one cycle
at 95uC for 0 s, 40uC for 60 s and 90uC for 0 s; and cooling
program, one cycle at 40uC for 60 s. The temperature transition
rate was 20uC/s, except in the melting program, that was 0.4uC/s
between 40 and 90uC. In order to reduce the variation between
different assays and samples, a procedure based on the relative
quantification of target genes versus their controls in relation to the
reference gene was used. Calculations were automatically
performed by LightCycler software (RealQuant, version 1.0,
Roche Molecular Biochemicals, Mannheim, Germany). The
normalized ratio was obtained from the next equation and
expressed as a percentage of the control:
Normalizedratio (N)~
(Etarget)
Dcp target(control{sample).
(Eref)
DCp ref(control{sample)
Efficiencies (E) for each gene were calculated from the slopes of
crossover points (Cp) vs. cDNA concentration plot, according to
the formula E=10(-1/slope). DCp corresponds to the difference
between control Cp and sample Cp, either for the target or for the
reference genes. The selected control was a bone marrow
specimen from a healthy donor and was considered as 100%
expression. Occasionally, equal amounts of PCR products were
separated on a 2% agarose gel, stained with ethidium bromide and
visualized under UV light.
Q-RT-PCR for hsa-miR-34b/c
Total RNA was extracted with Ultraspec (Biotecx, Houston,
TX, USA) following the manufacturer’s instructions. RNA
concentration was quantified using NanoDrop Specthophot-
ometer (NanoDrop Technologies, USA). 5 ng of total RNA was
used to synthesize a specific cDNA of the hsa-miR-34b and -34c
using a stem-loop miRNA-specific RT primer according to the
TaqMan MicroRNA Assay protocol (Applied Biosystems, Foster
City, CA). Reverse transcriptase reactions contained 1.5 mlo f
miRNA-specific stem-loop RT primer and 6 ml of Master Mix
composed of 2 ng of RNA, 1x RT buffer, 0.25 mM of each dNTP,
3.33 U/ml of MultiScribe reverse transcriptase and 0.25 U/mlo f
RNase Inhibitor (Applied Biosystems, Foster City, CA, USA). The
7.5 ml reactions were incubated in a 2720 Thermal Cycler
(Applied Biosystems, Foster City, CA) for 30 min at 16uC,
30 min at 42uC, 5 min at 85uC and then maintained at 4uC.
Expression of the hsa-miR-34b and -34c was analyzed using specific
primers and TaqMan probe (PD4373037 for hsa-miR-34b and
PD4373036 for hsa-miR-34c) according to the TaqMan Micro-
RNA Assay protocol (Applied Biosystems, Foster City, CA).
Quantitative real time-PCR (Q-RT-PCR) was performed in a
7300 Real Time System (Applied Biosystems, Foster City, CA),
using 0.7 ml of RT product of hsa-miR-34b or -34c in a reaction
volume of 10 ml with 1x TaqMan Universal PCR master mix and
1 ml of primers and probe mix according to the TaqMan
MicroRNA Assay protocol (PE Applied Biosystems, Foster City,
CA). The reactions were incubated at 95uC for 10 min, followed
by 45 cycles of 95uC for 15 s and 60u for 30 s. The Ct data was
determined using default threshold settings. The threshold cycle
(Ct) is defined as the fractional cycle number at which the
fluorescence passes the fixed threshold. Expression of hsa-miR-34b
and -34c were normalized using the expression of RNU6B gene in
each sample. For expression of RNU6B we used TaqMan RNU6B
assay (PN: 4373381) (Applied Biosystems, Foster City, CA). The
normalized ratios of hsa-miR-34b and -34c expression were
calculated as described above. The selected control/calibrator
was the bone marrow lymphocytes from a healthy donor that was
considered as 100% of hsa-miR-34b or -34c expression.
Cell treatments
TOM-1 and NALM-20 ALL-derived cell lines were treated
with the demethylating agents 5-aza-2’-deoxycytidine (diluted in
1:1 water:acetyc) at 0.5, 2 and 4 mM (Sigma Aldrich, Steinheim,
Germany); the caspase 8 activator Curcumin (diluted in DMSO)
at 12.5 and 25 mM (Sigma Aldrich, Steinheim, Germany) and with
the MDM2 inhibitor Nutlin-3 (diluted in DMSO) at 10 and
15 mM (Sigma Aldrich, Steinheim, Germany).
Western blotting
Cells pellets were resuspended in lysis buffer containing 1%
Triton X-100, 50 mM Tris HCl (Ph=8), 150 mM NaCl, 1 Mm
NaVO4, 10 mM NaF and 1X complete (Roche, Mannheim,
Germany) for 30 minutes at 4uC. After centrifugation at
13000 rpm for 15 minutes at 4uC the supernatant was collected
as whole cell lysates. Protein concentration was determined with
the BCA assay (Pierce Chemical, West Pico, Rockville, IL). Equal
amounts of protein (15 mg/lane for nuclear and cytoplasmic
extract and 50 mg/lane for total extracts) were separated by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred onto a nitrocellulose membrane (Bio-Rad,
Hercules, CA). The membranes were blocked for 1 hour with
0.1% Tropix in 0.01% Tween 20 PBS and incubated with a
monoclonal antibody against PARP p85 (1:1000 for 1 hour at
room temperature (RT) (Promega, Madison, WI), p-Tyr* (1:1000
for 1 hour at RT. 05-321, Upstate), ABL1 (1:2000 for 3 hours at
RT. sc-23, Santa Cruz Biotechnology), Caspase-8 (1:2000, o/n at
RT. 9746, Cell Signaling), p53 (1:5000 for 2 hours at RT. P6874,
TP53 Pathway Methylation in ALL
PLoS ONE | www.plosone.org 11 February 2011 | Volume 6 | Issue 2 | e17012Sigma, St. Louis, MO), p21 (1:1000, o/n at 4uC. 556430,
PharMingen), Histone 3 (1:50000 for 2 hour at RT. 06-599.
Millipore, Billerica, MA01821, USA) and acetyl Histone 3
(1:20000, o/n at 4uC. 07-690. Millipore, Billerica, MA01821,
USA). Antibody against b-actin (1:4000 for 1 hour at RT. Sigma,
St. Louis, MO) was used to confirm equal loading of nuclear,
cytoplasmic, and total extracts, respectively. Secondary antibody
coupled with alkaline phosphatase (1:10000 at RT. Sigma, St.
Louis, MO) were added for an additional 1 hour. Inmunoreactive
bands were developed using a chemiluminescent substrate (CSPD,
Tropix) and Hyperfilm ECL plus films (Amersham, Arlington,
Heights, IL). An autoradiograph was obtained with exposure times
from 1 to 10 minutes.
Apoptosis analysis
The apoptosis was studied by Annexin V and Caspase-3
analysis by flow citometry and the detection of the 85-kDa
fragment of PARP by western blot. Annexin V apoptosis analysis:
Cell death and apoptosis were determined by staining cells with
annexin-V-FITC and counterstaining with propidium iodide (PI)
using the FITC Annexin V Apoptosis Detection Kit I (BD
Pharmingen, San Diego, CA) following the manufacturers
instructions. Analyses were performed 24 hours after treatment
on FACscan (Becton –Dickinson, Heilderberg, Germany), using
the CellQuest analysis software. Viable cells with intact mem-
branes exclude PI, whereas the membranes of dead and damage
cells are permeable to PI. The FITC Annexin V staining precedes
the loss of membrane integrity which accompanies the latest stages
of cell death resulting from either apoptotic or necrotic processes.
Therefore, cells which were Annexin-V-FITC-negative and PI-
negative were classified as living cells, while PI-positive cells were
classified as necrotic. Annexin-V-FITC-positive but PI negative
cells were classified as early apoptotic as they present membrane
integrity. The mean percentage of cells expressing annexin V, PI
or both is shown. Active Caspase-3 apoptosis analysis: The FITC-
Conjugated Monoclonal Active Caspase-3 antibody apoptosis Kit
(BD Pharmingen, San Diego, CA) was used following the
manufacturers instructions. The mean percentage of cells
expressing active caspase-3 is shown.
Statistical analysis
Remission status was assessed after completion of induction
chemotherapy. Complete remission (CR) was defined as follows:
granulocyte count of at least 1610
9/l, platelet count of at least
100610
9/l, no PB blasts, BM cellularity of at least 20% with
maturation of all cell lines and less than 5% blasts, no
extramedullary leukemia. Primary therapy failure was defined as
persistence of PB blasts or at least 25% blasts in BM after
induction therapy. Relapse was defined as reappearance of PB
blasts, more than 5% blasts in BM, or appearance of extramed-
ullary manifestations after CR was achieved. Overall survival (OS)
was measured from the day of diagnosis until death from any cause
and was censored only for patients known to be alive at last
contact. Disease-free survival (DFS) was measured from the day
that CR was established until either first relapse or death without
relapse, and it was censored only for patients who were alive
without evidence of relapse at the last follow-up. Event-free
survival (EFS) was defined as time from study entry until removal
from study because of failure to achieve complete remission, first
relapse, or death from any cause. All relapse and survival data
were updated on May, 2009, and all follow-up data were censored
at that point. Patients who underwent SCT were included but
censored at the date of transplant.
For statistical purposes, ALL patients were classified into two
different methylation groups: Non-methylated (no methylated
genes) and methylated group (at least, one methylated gene). The
rationale for grouping patients with any methylated gene
(regardless of the number of methylated genes) in the same
methylation group was derived after statistical analyses for OS and
DFS according to the number of genes methylated (from 0 to 9; no
patients showed methylation of more than nine genes). Results of
these analyses showed that prognosis for non-methylated patients
were better than patients with methylated genes. Moreover,
prognosis of patients with 1 to 9 methylated genes was similar with
no statistical differences (data not shown). Comparisons of
molecular and clinical features across groups were performed
using the 2 or a 2-sided Fisher exact test for categorical data and
the nonparametric Mann-Whitney U test for continuous variables.
A P value less than or equal to .05 (2-sided) was considered
significant. Distributions of OS, DFS and EFS curves were
estimated by the method of Kaplan and Meier, with 95%
confidence intervals calculated by means of Greenwood’s formula
and with the log-rank comparing differences between survival
curves. Hazard ratios comparing DFS, EFS, and OS between
subgroups were calculated using univariate Cox models. Multi-
variate Cox regression modeling was done for DFS, EFS and OS
using a forward-selection stepwise modeling process (with a
forward selection method with entry probability of P=.01. using
Wald CIs and with stepwise removal of non-significant factors); the
difference in the log likelihood (226log likelihood) was used,
along with an adjustment for phase of trial (PETHEMA ALL89 vs
PETHEMA ALL93). Factors were entered as categorical values as
far as possible to keep the computations simple, although
categorization inevitably results in some loss of information. All
variables in the model were linear and conformed to the
proportional hazards assumption. The following variables were
considered in the model: age (#15 vs. .15 years), methylation
profile (negative vs. positive), WBC (#50610
9/l vs. .50610
9/l,
BCR-ABL (negative versus positive), cell immunophenotype (B
versus T) and PETHEMA risk groups (high versus others). For
children we also included TEL-AML1 (positive versus Negative)
and NCI risk groups (high versus others).
Supporting Information
Figure S1 Definition of methylation analysis thresholds
based on the distribution of bad detection p values
(p.0.01). A) Threshold definition per CpG. A total of 1505
CpGs were studied with the bead array. The threshold of 15% was
set based on visual inspection of this distribution (i.e. the estimated
inflexion point). Based on this threshold, a total of 60 CpGs (the
right peak of the plot) showed bad p values in 15% or more of the
cases. B) Threshold definition per case. A total of 69 hybridizations
were performed including ALLs and controls. As shown in the
figure, low numbers of bad p values (ranging from 1 to 5%) are
seen in the first 64 hybridizations. However, the 5 cases showed a
clearly higher percentage of bad p values, Based on this
distribution, we set a threshold for case selection of 5% (i.e. a
case is selected for further statistical analyses if 95% or more CpGs
show good p values).
(TIF)
Figure S2 Hierarchical clustering analysis of DNA
methylation data. Dendrogram of hierarchical cluster analysis
based on the methylation status of CpG regions from ALL and
control samples. The top bar beneath the dendrogram refers to the
subtypes of ALL and specific controls from healthy donors, while
the lower bar indicates ALL or control. Subtypes of leukemia or
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PBMNC: Peripheral Blood mononuclear cells from healthy
donors, CD19
+ cells from PB and CD3
+ cells from PB). Red:
methylated; Green: non-methylated.
(TIF)
Figure S3 MSP melting curve analysis of the methylated
sequences. The presence of specific methylated products is shown
by the melting curves obtained by means of a LightCycler 2.0 PCR
real time device. Green: positive methylated control; pink:
peripheral blood lymphocytes from healthy donors; yellow: blank
control (water); red: TOM1 cell line; blue: NALM-20 cell line.
(TIF)
Figure S4 Comparison results obtained by Illumina
Beadarray, Methylation Specific PCR (MSP) and pyro-
sequencing. A. Bead array methylation results. B. MSP results
in same sample used in the bead array. Because several CpG for
each gene on the array have been analyzed (A) and we have only
one result of MSP (B), some of the MSP rows have been
duplicated/triplicated to equal the number of CpGs. PB:
Peripheral Blood of healthy donor, MC: human male genomic
DNA universally methylated for all genes, Red: methylated,
Green: non methylated. C. Pyrosequencing results of analyzed
CpG loci on the array, corresponding to MGMT, SYK and TAL1
genes. The values are expressed as percentage of methylation.
(TIF)
Figure S5 DNA methylation and expression analysis of
hsa-miR-34b/c, POU4F1, POU4F2 and AMID in ALL cell
lines. A. Q-MSP analysis of hsa-miR-34b/c, POU4F1, POU4F2 and
AMID before and after treatment with 5-Aza-29-deoxycytidine in
ALL cell lines. B. Pyrosequencing analysis of -miR-34b/c,
POU4F1, POU4F2 and AMID before and after treatment with 5-
Aza-29-deoxycytidine in ALL cell lines. X axis shows the different
loci analyzed. C. Q-RT-PCR analysis of hsa-miR-34b/c, POU4F1,
POU4F2 and AMID before and after treatment with 5-Aza-29-
deoxycytidine in ALL cell lines. AZA: 5-Aza-29-deoxycytidine. PB:
Peripheral Blood sample.
(TIF)
Table S1 Clinical characteristics and outcome of 200
ALL patients according to gene methylation status.
(DOC)
Table S2 Primers corresponding to methylated reac-
tions of genes.
(DOC)
Table S3 Primers corresponding to unmethylated reac-
tions of genes.
(DOC)
Table S4 Specific primers and probes corresponding to
pyrosequencing analysis.
(DOC)
Table S5 Beta value and genes differentially methylated
in more than 10% of ALL samples. Different subtypes of
leukemia or controls are color-coded. PB: Peripheral Blood
mononuclear cells from healthy donors; CD3: CD3+ cells from
PB and CD19: CD19+ cells from PB. PcG: targets of polycomb
repressive complex 2 (PRC2). Light Red: genes hypermethylated
in more than 10% of ALL samples. Light Green: genes
hypomethylated in more than 10% of ALL samples.
(XLS)
Table S6 Multivariate Cox Model for Disease Free
Survival (DFS).
(DOC)
Table S7 Multivariate Cox Model for Overall Survival
(OS).
(DOC)
Table S8 Multivariate Cox Model for Event-free surviv-
al (EFS).
(DOC)
Table S9 Specific primers and probes corresponding to
Q-RT-PCR analysis.
(DOC)
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